tbuckley/cabot-search huggingface dataset:
Biomineralized Bimetallic Oxide Nanotheranostics for Multimodal Imaging-Guided Combination Therapy
Authors: Jianrong Wu, Gareth R. Williams, Shiwei Niu, Yanbo Yang, Yu Li, Xuejing Zhang, Li-Min Zhu
Journal: Theranostics (2019)

The hypoxia of the tumor microenvironment (TME) often hinders the effectiveness of cancer treatments, especially O 2 -dependent photodynamic therapy (PDT).Methods: An integrated iridium oxide (IrO 2 )-manganese dioxide (MnO 2 ) nanotheranostic agent was fabricated through bovine serum albumin (BSA)-based biomineralization of Ir 3+ and Mn 2+ .BSA was first covalently modified with chlorin e6 (Ce6), and used to fabricate multifunctional BSA-Ce6@IrO 2 /MnO 2 nanoparticles (NPs) for computed X-ray tomography (CT) and photoacoustic (PA) imaging-guided PDT and photothermal (PTT) therapy of cancer.Extensive in vitro and in vivo studies were performed.Results: The theranostic agent produced can relieve tumor hypoxia by the decomposition of endogenous H 2 O 2 in cancer cells to oxygen.The oxygen generated can be exploited for improved PDT.Paramagnetic Mn 2+ released from the NPs in the acidic TME permits magnetic resonance imaging (MRI) to be performed.The exceptional photothermal conversion efficiency (65.3%) and high X-ray absorption coefficient of IrO 2 further endow the NPs with the ability to be used in computed CT and PA imaging.Extensive antitumor studies demonstrated that the BSA-Ce6@IrO 2 /MnO 2 nanoplatform inhibits cancer cell growth, particularly after combined PTT and PDT.Systematic in vivo biosafety evaluations confirmed the high biocompatibility of the nanoplatform.Conclusion: This work not only provides a novel strategy for designing albumin-based nanohybrids for theranostic applications but also provides a facile approach for extending the biomedical applications of iridium-based materials.
Serial assessment of humoral immunity in pediatric AML: A prospective study.
Authors: Sameer Bakhshi, Anuj Kumar Bansal, Surender Kumar Sharawat, Ritu Gupta, Vishnu kumar Sreenivas
Journal: Journal of Clinical Oncology (2012)

9551 Background: Humoral immunity has been evaluated in pediatric ALL; data in pediatric AML is lacking. The objectives of this study were to assess humoral immunity on follow-up in pediatric AML patients. Methods: From April 2010-May 2011, 45 consecutive AML patients 1-18 years old were prospectively enrolled with 7 healthy controls. Immunoglobulin (Ig) levels in 45 patients and B-lymphocytes (CD19+) in 29 patients were assessed at diagnosis, post-induction, post-consolidation, 3 and 6 months follow-up and relapse. Results: At diagnosis, Ig levels were higher in patients as compared to healthy controls (IgG, p=0.041; IgA, p=0.07; IgM, p=0.16) while B-cells were lower (p=0.001). Patients with gum hypertrophy had low Ig levels (IgG, p=0.007; IgA, p=0.003; IgM, p=0.06). CR rate was 84.4% (38/45); EFS 40% and OS 58% at 20 months follow-up. Post-induction, there was reduction in IgM (p&lt;0.001) and IgA (p=0.048) levels and increase in B cells (p&lt;0.001). Using generalized estimating equation regression model, average reduction from post-induction till 3 month follow-up was 36.9 units/visit (IgG); 10.3 units/visit (IgA); 0.32 units/visit (IgM) in those with continuous CR (group-1, n=24) and 91 units/visit (IgG); 8.9 units/visit (IgA); 1.5 units/visit (IgM) in those who relapsed (group-2, n=14). Difference between these two groups was significant for IgA (p=0.017). There was increase in IgG (p=0.52) and IgA levels (0.21) at relapse when compared with post-consolidation values. B-cells had an average increase of 3.6 units/visit (p=0.012) in group 1 and decrease of 0.58 units/visit (p=0.82) in group 2; (group-1 vs group-2, p=0.10). There was no significant correlation of baseline Ig and B cells with CR rate, EFS and OS. Conclusions: This is the first study to evaluate humoral immunity serially in pediatric AML. AML patients with gum hypertrophy have low IgG and IgA at diagnosis. On serial monitoring, B cells show an increase in patients who are in continuous CR while those who relapse tend to show a reduction on follow-up. Further, on follow-up, although all Ig decrease, but the reduction in IgA is significantly lower in patients who relapse suggesting their possible role in disease biology.
Clinical Practices for Measles-Mumps-Rubella Vaccination Among US Pediatric International Travelers
Authors: Emily P. Hyle, Sowmya R. Rao, Audrey C. Bangs, Paul Gastañaduy, Amy Parker Fiebelkorn, Stefan H.F. Hagmann, Allison Taylor Walker, Rochelle P. Walensky, Edward T. Ryan, Regina C. LaRocque
Journal: JAMA Pediatrics (2019)

The US population is experiencing a resurgence of measles, with more than 1000 cases during the first 6 months of 2019. Imported measles cases among returning international travelers are the source of most US measles outbreaks, and these importations can be reduced with pretravel measles-mumps-rubella (MMR) vaccination of pediatric travelers. Although it is estimated that children account for less than 10% of US international travelers, pediatric travelers account for 47% of all known measles importations.To examine clinical practice regarding MMR vaccination of pediatric international travelers and to identify reasons for nonvaccination of pediatric travelers identified as MMR eligible.This cross-sectional study of pediatric travelers (ages ≥6 months and <18 years) attending pretravel consultation at 29 sites associated with Global TravEpiNet (GTEN), a Centers for Disease Control and Prevention-supported consortium of clinical sites that provide pretravel consultations, was performed from January 1, 2009, through December 31, 2018.Measles-mumps-rubella vaccination among MMR vaccination-eligible pediatric travelers.Of 14 602 pretravel consultations for pediatric international travelers, 2864 travelers (19.6%; 1475 [51.5%] males; 1389 [48.5%] females) were eligible to receive pretravel MMR vaccination at the time of the consultation: 365 of 398 infants aged 6 to 12 months (91.7%), 2161 of 3623 preschool-aged travelers aged 1 to 6 years (59.6%), and 338 of 10 581 school-aged travelers aged 6 to 18 years (3.2%). Of 2864 total MMR vaccination-eligible travelers, 1182 (41.3%) received the MMR vaccine and 1682 (58.7%) did not. The MMR vaccination-eligible travelers who did not receive vaccine included 161 of 365 infants (44.1%), 1222 of 2161 preschool-aged travelers (56.5%), and 299 of 338 school-aged travelers (88.5%). We observed a diversity of clinical practice at different GTEN sites. In multivariable analysis, MMR vaccination-eligible pediatric travelers were less likely to be vaccinated at the pretravel consultation if they were school-aged (model 1: odds ratio [OR], 0.32 [95% CI, 0.24-0.42; P < .001]; model 2: OR, 0.26 [95% CI, 0.14-0.47; P < .001]) or evaluated at specific GTEN sites (South: OR, 0.06 [95% CI, 0.01-0.52; P < .001]; West: OR, 0.10 [95% CI, 0.02-0.47; P < .001]). The most common reasons for nonvaccination were clinician decision not to administer MMR vaccine (621 of 1682 travelers [36.9%]) and guardian refusal (612 [36.4%]).Although most infant and preschool-aged travelers evaluated at GTEN sites were eligible for pretravel MMR vaccination, only 41.3% were vaccinated during pretravel consultation, mostly because of clinician decision or guardian refusal. Strategies may be needed to improve MMR vaccination among pediatric travelers and to reduce measles importations and outbreaks in the United States.
Impact of a Risk-Adapted Treatment Approach in Pediatric AML: A Report of the AML-BFM Registry 2012
Authors: Mareike Rasche, Emma Steidel, Denise Kondryn, Nils Von Neuhoff, Lucie Sramkova, Ursula Creutzig, Michael Dworzak, Dirk Reinhardt
Journal: Blood (2019)
CT7 (MAGE-C1)-Specific Cellular Immune Responses in the Bone Marrow Microenvironment of Multiple Myeloma Patients.
Authors: Hearn J. Cho, Len Farol, Jonathan T. Truong, Wayne R. Austin, Yao-Tseng Chen, Nina Bhardwaj, Ruben Niesvizky, Lloyd J. Old, Selina Chen-Kiang
Journal: Blood (2005)
NAD-Dependent Histone Deacetylase, SIRT1, Plays Essential Roles in the Maintenance of Hematopoietic Stem Cells.
Authors: Sachiko Ezoe, Itaru Matsumura, Hirokazu Tanaka, Hirohiko Shibayama, Masao Mizuki, Yuzuru Kanakura
Journal: Blood (2006)
Low Platelet Counts: Diagnosis Using Flow Cytometry and Anti Platelet Antibody.
Authors: Joao Carlos C. Guerra, Ruth H. Kanayama, Sonia S. Nozawa, Marcia R. Ioshida, Irina Y. Takihi, Robson J. Lazaro, Nelson Hamerschlak, Luiz Gastao M. Rosenfeld, Celso Carlos C. Guerra, Nydia S. Bacal
Journal: Blood (2006)
Sports concussions: can head impact sensors help biomedical engineers to design better headgear?
Authors: Lyndia Wu
Journal: British Journal of Sports Medicine (2019)

Sport-related concussion is a major public health concern. In a recent BJSM publication, McGuine et al conducted a randomised controlled trial (RCT) to evaluate whether soccer headgear would reduce the rate or severity of concussions in adolescent athletes (nheadgear = 1505, nno_headgear = 1545).1 Both ‘control’ athletes (who wore no helmets) and the athletes who wore soccer headgear had similar concussion rates and recovery times after a concussion. In another study, headgear was also found to be ineffective in reducing concussion rates or recovery times in rugby union.2

Padding may seem like the most intuitive way to protect the head from injury. So why might this approach not be concussion-proof? Adding a foam pad can help ‘soften the blow’, by increasing the loading area and absorbing some of the impact energy. However, given a regular thickness pad, substantial impact energy is still transmitted to the head and produces a sharp head/skull acceleration. The skull acceleration in turn shakes and deforms its contents—the brain.

Traditionally designed helmets and padding reduce focal loading and head linear accelerations that are associated with skull fracture risk.3 However, head rotation has been hypothesised to be a …
Stretchable Devices: Donut‐Shaped Stretchable Kirigami: Enabling Electronics to Integrate with the Deformable Muscle (Adv. Healthcare Mater. 23/2019)
Authors: Yusuke Morikawa, Shota Yamagiwa, Hirohito Sawahata, Rika Numano, Kowa Koida, Takeshi Kawano
Journal: Advanced Healthcare Materials (2019)

Stretchable electronics are significantly used to integrate electronic devices with soft biological tissues. However, conventional stretchable devices have limited applications because of their higher Young's modulus and instability in wet environments. In article number 1900939, Takeshi Kawano and co-workers propose a donut-shaped-kirigami device that can envelop the muscle, allowing the device to stretch and follow muscle deformation and robust EMG signal recordings.
Magnetic resonance imaging with concentric shrinkage as a prognostic factor in patients with luminal breast cancer during neoadjuvant chemotherapy.
Authors: Ippei Fukada, Shunji Takahashi, Masahiko Tanabe, Kazuhiro Araki, Takayuki Kobayashi, Kokoro Kobayashi, Naoya Gomi, Rie Horii, Futoshi Akiyama, Takuji Iwase, Yoshinori Ito
Journal: Journal of Clinical Oncology (2013)

e11587 Background: The important characteristics of breast cancer is its tumor heterogeneity and response to neoadjuvant chemotherapy (NAC). We analyzed the patterns of tumor shrinkage as a prognostic indicator after NAC for luminal breast cancer. Methods and Results. Methods: Of 854 patients who had received NAC in the single institute between January 2000 and December 2009, 265 luminal breast cancerwere retrospevively examined. Luminal breast cancer was defined as ER and/or PgR positive in more than 10% of cancer cells and HER2 negative (IHC 0, 1+ or FISH &lt;2.0). Before and after NAC, the primary lesion was evaluated by enhanced MRI in 235 patients. Results: The median follow-up period was 51.4 months. 38 patients(16.2%) experienced recurrence after a median DFI of 49.1 months. The median age was 50 and 232 patients received anthracycline containing chemotherapy and 179 patients received taxane. 120 out of 235 patients exhibited concentric shrinkage pattern. Multivariate analysis for DFS identified Age(49&gt;), strong ER/PgR positivity and concentric shrinkage as significantly favorable, and lymph node metastases as significantly unfavorable prognostic factors. Multivariate analysis for OS identified tumor size as significantly unfavorable prognostic factors(p=0.012). Conclusions: the tumor shrinkage pattern could be an important prognostic factor for luminal breast cancer and this suggests that a concentric shrinkage pattern of response may be infrequently associated with chemotherapy-resistant residual cancer cells.
Abstract 14217: Long Non-Coding RNA-Mediated Chromatin Remodeling in Diabetic Endothelial Dysfunction
Authors: Riccardo Calandrelli, Yingjun Luo, Kiran Sriram, Sheng Zhong, Zhen Chen
Journal: Circulation (2019)

Vascular endothelial cells (ECs) constitute the critical interface between circulating blood and vessel wall. Enhancers and long non-coding RNAs (lncRNAs) are important regulators in gene expressio...
Analysis of Chromosomal Aberrations and DNA Mutations in Bone Marrow Mesenchymal Stroma Cells from Patients with Myelodysplastic Syndrome Amd Acute Myeloid Leukemia
Authors: Olga Blau, Wolf-Karsten Hofmann, Igor W. Blau, Claudia D Baldus, Florian Nolte, Gundula Thiel, Elke Schuemann, Ouidad Benlasfer, Eckhard Thiel
Journal: Blood (2008)
A Genome-Wide Approach Identifies Variations in the Aspartate Metabolism Pathway That Are Associated with Asparaginase Sensitivity
Authors: Shih-Hsiang Chen, Wenjian Yang, Yiping Fang, Gabriele Stocco, Kristine R. Crews, Ching-Hon Pui, William E. Evans, Mary V. Relling
Journal: Blood (2008)
Predictors of hepatitis B and C virus reactivation in patients with psoriasis treated with biologic agents: a 9-year multicenter cohort study
Authors: Hsien-Yi Chiu, Ying-Ming Chiu, Nien-Feng Chang Liao, Ching-Chi Chi, Tsen-Fang Tsai, Chang-Yu Hsieh, Tsu-Yi Hsieh, Kuo-Lung Lai, Tsu-Man Chiu, Nan-Lin Wu, Rosaline Chung-yee Hui, Chaw-Ning Lee, Ting-Shun Wang, Po-Hua Chen, Chao-Chun Yang, Yu-Huei Huang
Journal: Journal of the American Academy of Dermatology (2019)
Human SNORA31 variations impair cortical neuron-intrinsic immunity to HSV-1 and underlie herpes simplex encephalitis
Authors: Fabien G. Lafaille, Oliver Harschnitz, Yoon Seung Lee, Peng Zhang, Mary L. Hasek, Gaspard Kerner, Yuval Itan, Osefame Ewaleifoh, Franck Rapaport, Thomas M. Carlile, Madalina E. Carter-Timofte, Dominik Paquet, Kerry Dobbs, Bastian Zimmer, Daxing Gao, Maria F. Rojas-Duran, Dylan Kwart, Vimel Rattina, Michael J. Ciancanelli, Jessica L. McAlpine, Lazaro Lorenzo, Soraya Boucherit, Flore Rozenberg, Rabih Halwani, Benoit Henry, Naima Amenzoui, Zobaida Alsum, Laura Marques, Joseph A. Church, Saleh Al-Muhsen, Marc Tardieu, Ahmed Aziz Bousfiha, Søren R. Paludan, Trine Hyrup Mogensen, Lluis Quintana-Murci, Marc Tessier-Lavigne, Gregory A. Smith, Luigi D. Notarangelo, Lorenz Studer, Wendy Gilbert, Laurent Abel, Jean-Laurent Casanova, Shen-Ying Zhang
Journal: Nature Medicine (2019)
A Waldenström’s Macroglobulinemia Case with Functional Class Switch Recombination.
Authors: Patricia Martín-Jiménez, Ramón García-Sanz, Enrique Ocio, María E. Sarasquete, Ana Balanzategui, Miguel Alcoceba, María C. Chillón, Carlos Santamaría, J.F. San Miguel, Marcos González
Journal: Blood (2006)
Valuing Chimeric Antigen Receptor T-Cell Therapy: Current Evidence, Uncertainties, and Payment Implications
Authors: Melanie D. Whittington, R. Brett McQueen, Jonathan D. Campbell
Journal: Journal of Clinical Oncology (2019)

Article Tools REVIEW ARTICLES Health Services and Outcomes Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.19.01558 Journal of Clinical Oncology - published online before print December 5, 2019 PMID: 31804859 Valuing Chimeric Antigen Receptor T-Cell Therapy: Current Evidence, Uncertainties, and Payment Implications Melanie D. Whittington, PhD1xMelanie D. WhittingtonSearch for articles by this author; R. Brett McQueen, PhD1xR. Brett McQueenSearch for articles by this author; and Jonathan D. Campbell, PhD1xJonathan D. CampbellSearch for articles by this author Show More 1University of Colorado Anschutz Medical Campus, Aurora, CO https://doi.org/10.1200/JCO.19.01558 First Page Full Text PDF Figures and Tables © 2019 by American Society of Clinical Oncology
Magnetic resonance (MR) imaging to assess the risk for disease progression in patients with stage I multiple myeloma (MMI) and monoclonal gammapathy of undetermined significance (MGUS).
Authors: Bv. Berg, Lucienne Michaux, Frédéric Lecouvet, Augustin Ferrant, Jacques Malghem, MA Labaisse, Baudouin Maldague, Jl. Michaux
Journal: Blood (1995)
Biochemical Characterization of Recombinant Von Willebrand Factor (VWF) with a Type 2B Mutation (P1337L) Coexpressed with a Type 1 VWF Defect (C275R): A Complex Molecular Defect in a Patient Previously Diagnosed with Type 2A Von Willebrand Disease (VWD).
Authors: Luciano Baronciani, Augusto B. Federici, Matteo Beretta, Giovanna Cozzi, Maria T. Canciani, Pier M. Mannucci
Journal: Blood (2004)
Detection of Actionable BCR-ABL1 Kinase Domain (KD) Mutations in Chronic Myeloid Leukemia (CML) Patients with Failure and Warning Response to Tyrosine Kinase Inhibitors (TKIs): Potential Impact of Next-Generation Sequencing (NGS) and Droplet Digital PCR (ddPCR) on Clinical Decision Making
Authors: Simona Soverini, Margherita Martelli, Luana Bavaro, Caterina De Benedittis, Alessandra Iurlo, Sara Galimberti, Patrizia Pregno, Massimiliano Bonifacio, Francesca Lunghi, Fausto Castagnetti, Gabriele Gugliotta, Gianantonio Rosti, Mario Tiribelli, Vanessa Velotta, Fabio Stagno, Antonella Russo Rossi, Mariella D'Adda, Claudia Baratè, Monica Crugnola, Luigiana Luciano, Maria Antonella Laginestra, Adam S Corner, Dianna Maar, Antonio Percesepe, Stefano Pileri, Fabrizio Pane, Giuseppe Saglio, Michele Baccarani, Giovanni Martinelli, Michele Cavo
Journal: Blood (2019)
The Hematopoietic Stem Cell Compartment Is Different in Polycythemia Vera and Idiopathic Myelofibrosis.
Authors: Chloe James, Frederic Mazurier, Ronan Chaligne, Sabrina Dupont, Francois Delhommeau, Stephane Giraudier, William Vainchenker, Hubert De Verneuil
Journal: Blood (2007)
Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study
Authors: Guillaume Manson, Alexandre Thibault Jacques Maria, Florence Poizeau, François-Xavier Danlos, Marie Kostine, Solenn Brosseau, Sandrine Aspeslagh, Pauline Du Rusquec, Maxime Roger, Maud Pallix-Guyot, Marc Ruivard, Léa Dousset, Laurianne Grignou, Dimitri Psimaras, Johan Pluvy, Gilles Quéré, Franck Grados, Fanny Duval, Frederic Bourdain, Gwenola Maigne, Julie Perrin, Benoit Godbert, Beatris Irina Taifas, Alexandra Forestier, Anne-Laure Voisin, Patricia Martin-Romano, Capucine Baldini, Aurélien Marabelle, Christophe Massard, Jérôme Honnorat, Olivier Lambotte, Jean-Marie Michot
Journal: Journal for ImmunoTherapy of Cancer (2019)

<h3>Background</h3> Paraneoplastic syndromes (PNS) are autoimmune disorders specifically associated with cancer. There are few data on anti-PD-1 or anti-PD-L1 immunotherapy in patients with a PNS. Our objective was to describe the outcome for patients with a pre-existing or newly diagnosed PNS following the initiation of anti-PD-1 or anti-PD-L1 immunotherapy. <h3>Methods</h3> We included all adult patients (aged ≥18) treated with anti-PD-1 or anti-PD-L1 immunotherapy for a solid tumor, diagnosed with a PNS, and registered in French pharmacovigilance databases. Patients were allocated to cohorts 1 and 2 if the PNS had been diagnosed before vs. after the initiation of immunotherapy, respectively. <h3>Findings</h3> Of the 1304 adult patients screened between June 27th, 2014, and January 2nd, 2019, 32 (2.45%) had a PNS and were allocated to either cohort 1 (<i>n</i> = 16) or cohort 2 (<i>n</i> = 16). The median (range) age was 64 (45–88). The tumor types were non-small-cell lung cancer (<i>n</i> = 15, 47%), melanoma (<i>n</i> = 6, 19%), renal carcinoma (<i>n</i> = 3, 9%), and other malignancies (<i>n</i> = 8, 25%). Eleven (34%) patients presented with a neurologic PNS, nine (28%) had a rheumatologic PNS, eight (25%) had a connective tissue PNS, and four (13%) had other types of PNS. The highest severity grade for the PNS was 1–2 in 10 patients (31%) and ≥ 3 in 22 patients (69%). Four patients (13%) died as a result of the progression of a neurologic PNS (encephalitis in three cases, and Lambert-Eaton syndrome in one case). Following the initiation of immunotherapy, the PNS symptoms worsened in eight (50%) of the 16 patients in cohort 1. <h3>Interpretation</h3> Our results show that PNSs tend to be worsened or revealed by anti-PD-1 or anti-PD-L1 immunotherapy. Cases of paraneoplastic encephalitis are of notable concern, in view of their severity. When initiating immunotherapy, physicians should carefully monitor patients with a pre-existing PNS.
The Hematopoietic Supportive Potential of Human Mesenchymal Stromal Cells Is Associated with Expression of Cadherins.
Authors: Christoph Roderburg, Anke Diehlmann, Frederik Wein, Anne Faber, Ulf Krause, Maria Frankhauser, Anja Seckinger, Anthony D. Ho, Wolfgang Wagner
Journal: Blood (2006)
抗血栓治疗知识（八）：特殊情况下的抗血栓治疗——儿童、易栓症患者及各种复杂情况
Authors: BerndJilma, SridharKamath, GregoryYHLip, 李海燕
Journal: BMJ (2004)

针对儿童的抗血栓治疗建议，大多数是以成人的随机研究或儿童的小规模交叉研究结果为基础(并且多为回顾性研究)。虽然儿童的抗栓治疗适应证与成人的相同，但需要进行冶疗的疾病种类不同于成人，例如，血栓栓塞的一些易患因素仅在儿童中出现。患儿多是由于潜在某种疾病或干预某种疾病而造成血栓栓塞，从而需要进行抗栓治疗。由于儿童的生理性变化可能改变血栓形成过程，并对机体抗血栓治疗的反应产生潜在影响，因此儿童的抗血栓治疗与成人不同。
Impact of Hematopoietic Stem Cell (HSC) Recruitment and Graft Composition on Transplant Outcome after Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT): A Study of the Société Française de Greffe de Moelle Osseuse et de Thérapie Cellulaire (SFGM-TC) Registry.
Authors: Thomas Prebet, Quoc-Hung Le, Jean-Michel Boiron, Didier Blaise, Anne Huynh, Ibrahim Yakoub-Agha, Hélène Esperou, Fréderic Garban, Jean Henri Bourhis, Mauricette Michallet
Journal: Blood (2005)
Heme Oxygenase 1 Deficiency Compromises Stress Responses of Hematopoietic Stem Cells.
Authors: Yu-An Cao, Amy J. Wagers, Holger Karsunky, Hui Zhao, Robert Reeves, Ronald J. Wang, David K. Stevenson, Irving L. Weissman, Christopher H. Contag
Journal: Blood (2006)